<- Go Home

Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF).

Market Cap

$103.7B

Volume

1.2M

Cash and Equivalents

$5.2B

EBITDA

$4.4B

Tax Rate Collected

N/A

Tax Rate Ratio

N/A

Gross Profit

$5.7B

Profit Margin

53.59%

52 Week High

$519.88

52 Week Low

$377.85

Dividend

N/A

Price / Book Value

6.64

Price / Earnings

-216.13

Price / Tangible Book Value

7.57

Enterprise Value

$94.2B

Enterprise Value / EBITDA

20.93

Operating Income

$4.2B

Return on Equity

-2.99%

Return on Assets

12.05

Cash and Short Term Investments

$6.5B

Debt

$1.8B

Equity

$15.6B

Revenue

$10.6B

Unlevered FCF

$3.1B

Sector

Biotechnology

Category

N/A

PREMIUM

Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).

Upgrade to Yellowbrick Premium

Company Stock Pitches